Podcasts about deep science ventures

Mark1 is a public benefit corporation focused on accelerating the commercialization of emerging industrial technologies and climate solutions. Spun out of Deep Science Ventures and the Rocky Mountain Institute, Mark1 offers early-stage project development support, front-end planning, and catalytic capital for innovative companies. By bridging the gap between technology development and project deployment, they help startups navigate the complexities of project financing, off-take agreements, and regulatory processes. Julian Ryba-White, Co-Founder and CEO of Mark1, was previously a Principal at Nokomis Energy, Senior Director at TenK Solar, and Manager at SolarCity. Here are five takeaways. Bridging the commercialization gap: Julian explains the unique challenges companies face when transitioning from technology development to project deployment and how Mark One supports this process through expertise and resources. Adoption readiness levels: Mark One introduces the concept of "adoption readiness levels" from the DOE to measure project viability and prepare companies for scaling. Catalytic capital: Julian details their funding approach, offering $300,000 to $500,000 tied to project milestones to de-risk development and align incentives. Holistic project development: Mark One's bespoke program identifies gaps in technology, finance, and equity, providing tailored support through a co-development agreement. Career advice for emerging professionals: Julian emphasizes the importance of patience, family time, and human connection in balancing personal and professional growth.

Welcome to The Orthogonal Bet, an ongoing mini-series that explores the unconventional ideas and delightful patterns that shape our world. Hosted by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Samuel Arbesman⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. In this episode, Sam speaks with Dominic Falcao, a founding director of Deep Science Ventures (DSV), which he created in 2016 after leading Imperial College London's science startup program. Deep Science Ventures takes a principled and problem-based approach to founding new deep tech startups. They have even created a PhD program for scientists specifically geared towards helping them create new companies. Sam wanted to speak with Dom to discuss the origins of Deep Science Ventures, as well as how to think about scientific and technological progress more broadly, and even how to conceive new research organizations. Dom and Sam had a chance to discuss tech trees and the combinatorial nature of scientific and technological innovation, non-traditional research organizations, Europe's tech innovation ecosystem, what scientific amphibians are, and the use of AI in the realm of deep tech. Produced by⁠ ⁠Christopher Gates⁠⁠ Music by⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠George Ko⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ & Suno

Dr Claire Thorne, co-CEO of Tech She Can, discusses her expectations from the next government to revamp the education curriculum for technology roles. She also addresses the various factors that impact why girls don't get into STEM, why a third of women are leaving the sector and the importance of investors being more conscious of who they're investing in. Thorne founded Tech She Can to help address the "nationwide" problem of too few women in technology roles. The aim of the charity is to see women play an equal role in creating and developing tech businesses, products, and services that will ultimately shape the world and make sure that tech works for everyone. Thorne, who has a PhD in physics, is also a venture partner at Deep Science Ventures, a VC firm funding startups focused on pharmaceuticals, climate, agriculture and computation sectors.

Jeremiah Lim, Director in the Sustainable & Impact Investment Banking group at Barclays, discusses how climate hardtech companies can raise debt / project finance to help grow and scale their businesses. He discusses how a climate tech startup can get ready to raise debt, considerations ahead of structuring offtake agreements, when to start collaborating with groups such as his, as well as his take on the “low hanging fruit” within climate tech or technologies that should be prioritized. ------------------------------------------------------------------------------------------------------Mentioned in the podcast:Mission Zero - https://www.missionzero.tech/Deep Science Ventures - https://deepscienceventures.com/UNDO - https://un-do.com/Barclays Sustainable Impact Capital: https://home.barclays/sustainability/addressing-climate-change/financing-the-transition/sustainable-impact-capital/------------------------------------------------------------------------------------------------------Connect with us:Email us: info@climatetech360.comHost: https://www.linkedin.com/in/samiaqaderGuest: https://www.linkedin.com/in/jeremiah-lim-cfa-4bb93060/

You probably already know why coral reefs are so important—after all, they're home to a quarter of all marine life. But do you know about seagrass?  Seagrass not only provides habitat for aquatic wildlife, but it accounts for 10% of oceanic carbon storage, despite only taking up less than one percent of the seafloor. It also produces oxygen, cleans the ocean, protects against coastal erosion and more. Sadly, humanity is destroying both coral reefs and seagrass forests, with oceanic warming and acidification taking a major toll, along with pollution and fishing. Because of us, the world's already lost half of all corals and a third of all seagrass just in the past few decades.  But what if humanity could be as effective at growing reefs and seagrass as we are at destroying them? Proving that is the goal of Reefgen, a startup pioneering not SaaS (software as a service) business model, but rather RaaS (robots as a service) business model. Reefgen has invented robots that can navigate marine environments with precision and plant baby grass and corals at rates that are orders of magnitude faster than a human could.  And there's a business in this RaaS model. Not only are companies that want to pay for eco-offsets willing to pay to robotically plant new reefs and grassbeds, but so do companies that economically depend on vibrant ocean ecosystems for their livelihoods.  Reefgen CEO Chris Oakes, a marine biologist turned venture capitalist turned entrepreneur talks about the company's trajectory, its pilot trials in Hawaii, California, Indonesia, and Wales, and how it's going to scale in order to turn the tides for our planet. Discussed in this episode Our past episodes with Coral Vita (coral restoration) and Drone Seed (forest restoration). BBC on Reefgen's seagrass work in Wales. ReefGen was birthed from Good Machines Studio. Reefgen's pending patent application Chefs using seagrass for rice! Chris recommends reading Why Startups Fail and Getting Things Done. More about Chris Oakes Christopher Oakes is a marine biologist who specializes in deep-tech product commercialization and corporate development. Oakes holds a B.A. and M.A. in Biology from Occidental College. Oakes has dedicated his career to molecular tools and diagnostics, robotics, sustainable aquaculture and venture building. As CEO of Reefgen, he is setting the company's vision around mechanizing nearshore planting operations and strategic direction to meet the scale of ecosystem restoration market needs in the face of climate change. During his time at Occidental, Chris worked with the Vantuna Research Group focusing on life history studies of nearshore marine fishes, marine environmental monitoring, time series analysis and spatial modeling. He also developed laboratory procedures and analytical techniques for morphology studies of gastropods. Former companies and roles include: COO Sustainable Ocean Alliance, VP Product and Market Development NovoNutrients, Development Manager Liquid Robotics, Regional Manager Laboratory Corporation of America, and Director of Strategic Alliances and Venture Portfolio at Deep Science Ventures. Chris is also a long-time board member and R&D chair at the non-profit Marine Applied Research and Exploration (MARE).

Sam Cryer earned his PhD in organic chemistry at Imperial College London developing novel solar materials. After post-docs at Queen Mary and UCL, he joined Deep Science Ventures as an analyst where he developed the idea for Thermulon and spun out the company; building the founding team and raising their subsequent investment rounds. He oversees all company strategy including chemical technology development activities and academic partnerships.Click here for the episode web page.For more insights straight to your inbox subscribe to the Future in Sight newsletter, and follow us on LinkedIn and Instagram.Brought to you by Re:Co, a market intelligence company helping clients achieve resilient competitive advantage in the long term.Produced by Chris AttawayArtwork by Harriet RichardsonMusic by Cody Martin

Main takeaways:1. The Genesis of Neobe Therapeutics: Pedro co-founded Neobe Therapeutics with the aim of addressing a significant issue in the pharmaceutical industry: drug resistance in cancer treatment. Approximately 20% of cancer patients don't respond to immunotherapies, which are drugs that activate an immune response against cancer. And that is the problem Pedro & his team are trying to solve - making these drugs work in more patients by breaking down their extracellular matrix. Neobe Therapeutics' groundbreaking approach involves using engineered bacteria to overcome drug resistance, offering hope for more effective treatment options.2. Harnessing the Power of Engineered Bacteria: Neobe Therapeutics designs bacteria that specifically target tumors, bypassing healthy tissues. By programming these bacteria to produce enzymes that can break down the extracellular matrix of drug-resistant tumors, they enable the cancer drugs to penetrate and effectively treat the tumors.3. Neobe's Unique Approach to Funding: Pedro explains that Neobe Therapeutics' approach to funding is quite different from traditional biotech startups. The company's strategy involves securing early-stage funding through organizations like Deep Science Ventures, which offers both financial support and mentorship. This approach allows Neobe to maintain control over their intellectual property and equity, providing them with more flexibility in their research and development process.4. Progress and Future Plans: Neobe Therapeutics has two products in its pipeline, targeting specific subtypes of colon and breast cancer. The company is currently raising funds to conduct pre-clinical work, with the aim of entering first-in-human trials by 2025 or 2026.5. Educating and Engaging the Community: Pedro acknowledges the importance of educating the public, the medical community, and regulators about the safety and efficacy of using engineered bacteria in cancer treatment. Neobe Therapeutics is committed to working closely with all stakeholders to ensure their approach gains acceptance and becomes a viable option for cancer patients.Conclusion:Neobe Therapeutics is paving the way for a new era in cancer treatment by harnessing the power of engineered bacteria. With a unique approach to funding, a focus on education and engagement, and a dedicated team working tirelessly to develop innovative solutions, the company holds great promise in the fight against drug-resistant cancers. As Neobe continues its journey towards bringing these groundbreaking therapies to market, we eagerly anticipate the positive impact they will have on the lives of countless cancer patients.

Learn more about Inside Matters - https://insidematters.health/ In this week's episode, James has a lively discussion with Dominic Falcão about science, new technologies, starting and securing funding for tech companies and their personal philosophies and outlooks when it comes to development. Dominic is a co-founder of Deep Science Ventures (DSV), a company that focuses on four key outcomes: restorative cultivation, scaling intelligence, reversing global heating and curative therapeutics. He previously led Imperial College London's science startup programme: worked with over 200 student companies, and supported a fraction of these to raise over £25m in funding within 3 years. Dom admits to being obsessed with building new companies to solve the climate crisis, from carbon-neutral fuels and negative emissions technologies to market-side interventions to funnel more finance profitably into climate solutions. Via DSV, they are championing the diversity of background and vocation of focus in STEM education, starting with a global, diversity-led venture-focused science PhD programme.

In this week's episode, Desiree speaks with Mai Bui, Shiladitya Ghosh, and Nicholas Chadwick on a variety of topics related to carbon dioxide removal. We talk about the latest research around direct air capture hubs, technical differences between direct air capture and point source capture, challenges in commercializing DAC technologies, and advice for everyday people to support this industry.    Mai is currently a researcher at Imperial College informing policymakers with multiscale perspectives on a variety of carbon removal technologies. She also works heavily with the UKRI in completing due diligence on industrial decarbonization technologies and sits on the technical advisory board of Puro.earth, the world's largest crediting platform for engineered carbon removal.     Shiladitya and Nicholas both met at Deep Science Ventures, a deep-tech venture builder based in the UK. Shiladitya is the Co-founder and Chief Product Officer of Mission Zero Technologies. Previously, he completed his PhD at Imperial College in post-combustion carbon capture and thermochemical energy storage. Nicholas is the CEO and Co-Founder of Mission Zero Technologies and prior to founding Mission Zero, he completed his PhD in Chemistry at UCL focusing on water sensing and semiconductors.    Selected resources:   https://www.stateofcdr.org/resources  https://nanransohoff.substack.com/p/finding-a-job-in-climate    Email for suggestions -   podcast.greenminds@gmail.com 

This week's podcast guests are Laura Fletcher, head of business development and strategic partnerships at Deep Science Ventures; Matthias Steger, CEO of Endogena Therapeutics; Rodolphe Besserve, CEO, and Georges Rawadi, chief of biotech studio development, at eureKARE; and Biotech Growth Trust portfolio manager, Geoff Hsu.News: 02:30Endogena Therapeutics 5:10eureKARE 21:00Deep Science Ventures 33:46Biotech Growth Trust 47:44Endogena Therapeutics Inc. has announced the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP).RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of vision, for which there is currently no treatment for most patients. It is a leading cause of inherited blindness, with an estimated 1.5 million people worldwide presently affected.eureKARE, an investment company focused on financing and building next generation biotech companies in the fields of synthetic biology, has launched its first synthetic biology studio in Belgium. eureKARE is developing a pan-European biotech studio network covering several areas where synthetic biology can create solutions and high market value products.The synthetic biology studios will focus on biomedical and other thematic applications in different European innovation hotspots. The strategy is based on identifying, selecting, and nurturing high-quality European science. The venture builder Deep Science Ventures (DSV) has expanded an existing alliance with Cancer Research UK's innovation-focused arm Cancer Research Horizons, with the mission to establish new oncology startups in the U.K.Just months after Cancer Research UK (CRUK) established its industry-orientated division Cancer Research Horizons, the research charity has doubled down on a collaboration with DSV, a U.K. venture builder operating in a range of sectors including biotech, agriculture and computation. According to the latest agreement, the partners will co-found startups working in up to 10 areas of oncology, such as improving the number of patients that can benefit from immuno-oncology treatments.The Biotech Growth Trust PLC, based in the UK, seeks capital appreciation through investment in the worldwide biotech industry. It invests in a diversified portfolio of shares and related securities in companies on a worldwide basis.Its portfolio is operated by U.S.-headquartered OrbiMed Capital LLC. Following the strong results of the previous year, the company's NAV (net asset value) per share total return dropped by 33.8%, compared to a 55.1% increase in 2021, and the share price total return was down 37.0%. However, ​​overall, since OrbiMed's appointment in 2005, and to the year end, The Biotech Growth Trust's NAV has increased by 861.6% or 14.3% per annum.In its annual report, the portfolio manager stated the company remains confident that there are a number of potential catalysts that could lead to a recovery in the biotechnology sector this year and into the future, and their overall investment strategy remains unchanged.

Our immune system is like an army, constantly fighting to keep invaders at bay. When faced with solid tumours, that army is at a major disadvantage. Tumours can build walls around themselves making it hard for the immune cells to penetrate and subsequently target the cancerous cells. https://www.neobetherapeutics.com/ (Neobe Therapeutics), a spinout of https://deepscienceventures.com/ (Deep Science Ventures) and https://www.cancerresearchuk.org/ (Cancer Research UK), is looking to an old idea of using bacteria to treat solid tumours by coupling this with the precision tools of synthetic biology. Their bacteria aim to slip behind the walls of these solid tumours and, like a Trojan horse, precisely attack them from within - tearing down the walls for the army of the immune system In this episode of BioInnovation Spotlight, we chat with Neobe founder Dr Pedro Correa de Sampaio about why he moved from academia to entrepreneurship to tackle problems in cancer treatment, and why he believes this technology could be the solution.

Neobe Therapeutics is an early-stage startup engineering safe recombinant bacterial products to enable immune infiltration in solid tumors. Their bacterial products combine innate tumor colonization with genetically engineered inducible biosensors to disrupt tumor microenvironment barriers to infiltration. By enabling successful infiltration of immune excluded tumors using our bacterial products they will be able to multiply the number of patients that respond to existing immunotherapies, with a focus on checkpoint inhibitors. Neobe was formed in January 2021 in London, UK with the support of Deep Science Ventures and Cancer Research UK. The founding team is made up of Dr. Pedro Correa de Sampaio, a cancer biologist with a successful career studying the tumor microenvironment in top academic institutions in the UK and the US; and Dr. Annelise Soulier, a microbiologist and molecular biologist with several years of experience engineering bacteria for therapeutic applications in one of the top UK companies in the field, having authored patents in the field and developed products that are currently in clinical trials. The founding team has the support of a world class advisory board, including top academic researchers and former C-level industry executives in the field. It was selected for the 2021 cohort of the highly prestigious Accelerate@Babraham in Cambridge, UK, won the London branch of the Imagine IF! healthcare startup competition and Neobe's co-founder Annelise Soulier was a finalists of the AIM-HI Women's Venture Competition. During its first year, Neobe developed the genetic tools necessary for the generation of its initial prototype, and established collaborations with top academic institutions such as the Barts Cancer Institute to initiate efficacy studies. Neobe was also recently awarded a collaborative Innovate UK Biomedical Catalyst grant, from the UK government, for the development of its second product at a total project cost of £505K.

Today's guest is Dominic Falcão, Founding Director of Deep Science Ventures.Deep Science Ventures is a venture studio and a fund that pioneers a new model for synthesizing knowledge, talent, and capital into optimal outcome-centric scientific ventures. DSV focuses on building high-growth, high-impact companies in "tough" sectors from energy and agriculture to pharmaceuticals and computing.With a decade's knowledge and experience in company building, Dom serves as Founding Director of Deep Science Ventures, where he focuses on energy and the net-zero transition. He co-founded Deep Science Ventures in 2016 at the age of 25. Before DSV, Dom led Imperial College London's science startup program. He worked with over 200 student companies and supported a fraction of these to raise over £25m in funding within three years. He grew the community 375% to 3000 scientists in 1 year. In 2021, Dom was named one of Forbes Finance Under 30. I was looking forward to sitting down with Dom because Deep Science Ventures' approach to company building is unique. He walks me through that approach and their go-to-market strategy. Dom explains his climate journey and what led him to found DSV. We also discuss why the current path from academic research to commercialization is difficult and compare DSV with a traditional fund. Dom and I's conversation is a must-listen.Enjoy the show!You can find me on twitter @jjacobs22 or @mcjpod and email at info@myclimatejourney.co, where I encourage you to share your feedback on episodes and suggestions for future topics or guests.Episode recorded July 28th, 2021For more information about Deep Science Ventures: https://deepscienceventures.com/ For more information about this episode, visit: https://myclimatejourney.co/episodes/dominic-falcao

In this episode we get into what Dom and deep science ventures have been working on for the past few years, and what there incredible focus will be on in the future.  The post #121 – Dom Falco Speaks about Deep Science Ventures 2020-2021 first appeared on Learning With Lowell.

Minter Dialogue Episode #364Dr Shama Rahman is an accomplished musician, vocalist, songwriter, with a PhD in philosophy, neuroscience and complexity. She has founded several initiatives including Jugular Productions, Deep Science Ventures and Neurocreate of which she is CEO. In this conversation with Shama, we discuss her pluri-disciplinarian approach, the concept and process of creativity viewed through neuroscience, how to get into the flow state of mind, what her startup Neurocreate is setting out to achieve and the role of AI/tech with creativity.If you've got comments or questions you'd like to see answered, send your email or audio file to nminterdial@gmail.com; or you can find the show notes and comment on minterdial.com. If you liked the podcast, please take a moment to rate/review the show on RateThisPodcast. Otherwise, you can find me @mdial on Twitter.Support the show (https://www.patreon.com/minterdial)

In this episode I talk to Mark Hammond about how Deep Science Ventures works, why the linear commercialization model leaves a lot on the table, and the idea of venture-focused research. Mark is the founder of Deep Science Ventures, an organization with a fascinating model for launching science-based companies. Mark has many crisply articulated theses about holes in the current system by which research becomes useful innovations and what we might do to fill them. Key Takeaways: There are many places where innovation is slow and incremental because everybody is focused on individual pieces: batteries are a great example here. The perception that deep/frontier/hard tech companies are riskier and take longer to provide returns may in fact be more grounded in popular perception than fact The factors that make translational research so expensive may not be inherent but instead driven by administrative overhead and the fact that much of it is pointed in the wrong direction. Resources Deep Science Ventures Mark on Twitter (@iammarkhammond) Systematised ‘quant’ venture in the sciences. LifeSciVC on biotech returns

My guest this week is an industry acclaimed A.I. Scientist, Tech Pioneer and Venture Partner at Deep Science Ventures, a venture-focused science institute where audacious entrepreneurial scientists explore solutions to the world’s challenges. She is an advisor to both the UK Parliament and the EU Technology Commission in matters of digitalisation and Big Data. Fortune and TIME have described her as one of Europe’s top talents in social engagement through technology, and FastCompany labelled her a “firestarter”.  Please welcome Inma Martinez. Bio Inma Martinez is an engaged figure in the entrepreneurial, innovation and digitalisation sectors. An industry recognised Artificial Intelligence and digital visionary that pioneered 1:1 personalisation in the early days of the mobile Internet, Inma has been credited to be part of the original development teams behind Wireless Access Protocol (WAP), mobile music and video streaming, wearable technologies, “widgets” – the precursors to mobile apps, and the “connected car” and smart cities development. She is an inspirational keynote speaker on the effects of A.I. and Automation, Man-Machine Collaborations and the accelerated digitalisation of life, work and play. Both governments and private corporations seek her advisory on how to address the digital challenges – she is currently an advisor to the board at the All Parliamentary Party Group on A.I. at the House of Lords, and has provided evidence at the EU Commission on A.I. and the misuse of citizen data in light of new GDPR policies. In parallel, Inma continues to commit her time to education at Imperial College London where she is is a guest lecturer at the MSc Management program, the MSc in Economics and the MSc Innovation, Entrepreneurship and Strategy, and to the mentorship of innovative technologies at Deep Science Ventures, a venture-focused science institute where audacious entrepreneurial scientists explore solutions to world’s challenges. Fortune and TIME have described Inma as one of Europe’s top talents in social engagement through technology, and FastCompany labelled her a “firestarter”. She has appeared in the international media as a tech commentator and written articles for a variety of media outlets. In 2018 she was listed at #1 amongst “The Top 10 Women Changing The Landscape Of Data In 2018” by Enterprise Management 360 and one of the top “50 A.I. Influencers To Follow On Twitter” by Cognilytica, an A.I. and Cognitive Sciences Research agency. Inma Martinez’s most requested keynotes focus on the digital acceleration affecting Life, Work and Play, and how businesses should reorganise within to leverage from this transformational forces and be more innovative. In addition, she often presents new approaches to emerging sectors such as IoT, Smart Cities and Artificial Intelligence deployed to create products and services.  Recorded: 25th April 2019 Links: More about Inma Martinez More about Maria Franzoni Ltd Connect with Maria on Linkedin Connect with Maria on FaceBook To book any of the speakers featured on the Speaking Business podcast, click here  

Today we are joined with Dominic Falcao, a founder of Deep Science Ventures which is an early stage venture builder where they bring together the business and science aspects to help form amazing teams with...

*Bonus Episode* Gemma moderated a panel at SXSW on building an ecosystem for science startups with Ana Florescu of Science Practice, Harry Destecroix of UnitDx, and Dominic Falcao of Deep Science Ventures. 

In our ninth episode, host Dr Claire O'Connell talks to Inma Martinez, venture partner at Deep Science Ventures. Inma shares her thoughts on artificial intelligence, real-world data and the future of robots. Music by Drake Stafford. Produced by Bureau. Inspirefest: The Podcast is proudly supported by The Digital Hub.